Atai Life Sciences Statistics
Total Valuation
FRA:9VC has a market cap or net worth of EUR 1.02 billion. The enterprise value is 952.42 million.
| Market Cap | 1.02B |
| Enterprise Value | 952.42M |
Important Dates
The next estimated earnings date is Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 214.34M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +7.97% |
| Shares Change (QoQ) | +11.51% |
| Owned by Insiders (%) | 0.38% |
| Owned by Institutions (%) | 16.68% |
| Float | 160.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 521.24 |
| PB Ratio | 8.36 |
| P/TBV Ratio | 8.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.37 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -14.58 |
Financial Position
The company has a current ratio of 4.02, with a Debt / Equity ratio of 0.08.
| Current Ratio | 4.02 |
| Quick Ratio | 3.81 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.15 |
| Interest Coverage | -32.97 |
Financial Efficiency
Return on equity (ROE) is -76.50% and return on invested capital (ROIC) is -34.53%.
| Return on Equity (ROE) | -76.50% |
| Return on Assets (ROA) | -29.51% |
| Return on Invested Capital (ROIC) | -34.53% |
| Return on Capital Employed (ROCE) | -58.41% |
| Revenue Per Employee | 36,410 |
| Profits Per Employee | -1.88M |
| Employee Count | 54 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -99,626 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +422.09% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +422.09% |
| 50-Day Moving Average | 4.29 |
| 200-Day Moving Average | 2.48 |
| Relative Strength Index (RSI) | 53.16 |
| Average Volume (20 Days) | 4,233 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.48 |
Income Statement
In the last 12 months, FRA:9VC had revenue of EUR 1.97 million and -101.67 million in losses. Loss per share was -0.59.
| Revenue | 1.97M |
| Gross Profit | 1.97M |
| Operating Income | -81.40M |
| Pretax Income | -101.86M |
| Net Income | -101.67M |
| EBITDA | -80.76M |
| EBIT | -81.40M |
| Loss Per Share | -0.59 |
Balance Sheet
The company has 81.70 million in cash and 9.98 million in debt, giving a net cash position of 71.72 million.
| Cash & Cash Equivalents | 81.70M |
| Total Debt | 9.98M |
| Net Cash | 71.72M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 122.55M |
| Book Value Per Share | 0.58 |
| Working Capital | 65.68M |
Cash Flow
In the last 12 months, operating cash flow was -64.35 million and capital expenditures -980,077, giving a free cash flow of -65.33 million.
| Operating Cash Flow | -64.35M |
| Capital Expenditures | -980,077 |
| Free Cash Flow | -65.33M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -4,140.32% |
| Pretax Margin | -5,181.03% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:9VC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.97% |
| Shareholder Yield | -7.97% |
| Earnings Yield | -9.92% |
| FCF Yield | -6.37% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:9VC has an Altman Z-Score of -3.06 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.06 |
| Piotroski F-Score | 3 |